Hanmi Pharmaceutical Company Limited: Essential Hypertension trials
The registry lists 12 Essential Hypertension studies with Hanmi Pharmaceutical Company Limited as lead sponsor. 0 are open to participants now and 0 have results posted.
Phase 2 3Phase 3 8No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential HypertensionCompletedNCT06438172Phase 3
- An Observational Study to Evaluate Effectiveness and Safety of Amosartan Plus TabletCompletedNCT05462535
- A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension PatientsCompletedNCT05450601Phase 3
- A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential HypertensionCompletedNCT05362110Phase 3
- Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension PatientsCompletedNCT05199129Phase 3
- A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential HypertensionCompletedNCT04959305Phase 2
- Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension PatientsCompletedNCT04830449Phase 3
- Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension PatientsCompletedNCT04820907Phase 3
- A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential HypertensionCompletedNCT03897868Phase 2
- Efficacy and Safety of Amlodipine and Losartan in Patients With Essential HypertensionCompletedNCT00942344Phase 2
- Efficacy/Safety of Amlodipine Plus Losartan Versus Losartan in Patients With Essential HypertensionCompletedNCT00940680Phase 3
- Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Essential HypertensionCompletedNCT00940667Phase 3